Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2006/326/80

Case C-448/06: Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland

ĠU C 326, 30.12.2006, p. 38–38 (ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, NL, PL, PT, SK, SL, FI, SV)

Date of document:
30/12/2006; Data tal-pubblikazzjoni
Author:
Il-Qorti tal-Ġustizzja
Form:
Informazzjoni ġudizzjarja

30.12.2006   

EN

Official Journal of the European Union

C 326/38

Reference for a preliminary ruling from the Verwaltungsgericht Köln (Germany) lodged on 2 November 2006 — Firma cp-Pharma Handels GmbH v Bundesrepublik Deutschland

(Case C-448/06)

(2006/C 326/80)

Language of the case: German

Referring court

Verwaltungsgericht Köln

Parties to the main proceedings

Applicant: Firma cp-Pharma Handels GmbH

Defendant: Bundesrepublik Deutschland

Question referred

Is Commission Regulation (EC) No 1873/2003 of 24 October 2003 (1) amending Annex II to Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (2) void on account of a breach of higher-ranking Community law (Articles 1(1) and 3 of Council Regulation (EEC) No 2377/90 in conjunction with Article 4(1) of Council Directive 96/22/EC of 29 April 1996 (3)), in so far as application of an injection solution as a pharmaceutical form is excluded by virtue of the note marked (*) against the listing of progesterone in Annex II to Council Regulation (EEC) No 2377/90?

(1)  OJ 2003 L 275, p. 9.

(2)  OJ 1990 L 224, p. 1.

(3)  OJ 1996 L 125, p. 3.

Top